Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Study Overview
=================
Brief Summary
-----------------
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Detailed Description
-----------------
The study will enroll 66 subjects in four cohorts. All subjects will receive a single administration of VXA-RSV-f at a low dose, a high dose or placebo. Two sentinel groups will enroll 3 subjects each in an open-label manner (Cohorts 1 and 3) to receive VXA-RSV-f prior to enrolling either of the randomized, controlled cohorts (Cohorts 2 and 4). Within the double-blinded Cohorts (2 and 4), placebo subjects will receive the same number of tablets as the vaccine subjects in that Cohort. Subjects will be enrolled and dosed in the low dose groups prior to initiation of dosing in the high dose group. Cohort 1: 3 subjects at low dose Cohort 2: 20 subjects at low dose and 10 placebo Cohort 3: 3 subjects at high dose Cohort 4: 20 subjects at low dose and 10 placebo Subjects will be followed for 28 days post vaccination for preliminary immunogenicity. Subjects will continue to be followed for 1 year post-vaccination for long term safety.

Official Title
-----------------
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers

Conditions
-----------------
Respiratory Syncytial Virus (RSV)

Intervention / Treatment
-----------------
* Biological: VXA-RSV-f Tablets (high dose)
* Other: VXA Placebo Tablets
* Biological: VXA-RSV-f Tablets (low dose)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female volunteers aged 18 - 49 years, inclusive Able to give written informed consent Healthy (no clinically significant health concerns) Safety laboratory values within the following range criteria normal range Body mass index between 17 and 35 at screening Exclusion Criteria: Receipt of any investigational RSV vaccine within two years prior to study Receipt of any investigational vaccine, drug or device within 8 weeks preceding vaccination Administration of any licensed vaccine within 30 days prior to study Presence of significant uncontrolled medical or psychiatric illness (acute or chronic) including institution of new medical/surgical treatment or significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months of screening and reconfirmed at baseline History of drug, alcohol or chemical abuse within 1 year prior to vaccination Presence of a fever ≥ 38oC measured orally at baseline Stool sample with occult blood at screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VXA-RSV-f Tablets (high dose)<br>Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV. | Biological: VXA-RSV-f Tablets (high dose)<br>* The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.<br>* Other names: RSV (high dose) Oral Vaccine Tablet;|
| Experimental: VXA-RSV-f Tablets (low dose)<br>Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV. | Biological: VXA-RSV-f Tablets (low dose)<br>* The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose<br>* Other names: RSV (low dose) Oral Vaccine Tablet;|
| Placebo Comparator: VXA Placebo Tablets<br>Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered. | Other: VXA Placebo Tablets<br>* The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.<br>* Other names: Placebo Control;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systemic Reactogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet. | Number of Patients with Systemic Reactogenicity Symptoms | Day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immunogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet. | Number of Patients with a >/= 4-fold Increase in Serum Neutralizing Antibodies from Baseline as determined by PRNT Assay | Day 28 | 
| Immunogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet (GMT) | Mean Geometric Mean Titer | Days 7 and 28 | 
| Immunogenicity of VXA-RSV-f vaccine delivered by oral enteric tablet (GMFR) | Mean Geometric Mean Fold Rise | Days 7 and 28 |